These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 18566379)

  • 21. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
    Baxevanis CN; Gritzapis AD; Tsitsilonis OE; Katsoulas HL; Papamichail M
    Int J Cancer; 2002 Apr; 98(6):864-72. PubMed ID: 11948464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
    Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
    Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.
    Kuznetsova M; Lopatnikova J; Khantakova J; Maksyutov R; Maksyutov A; Sennikov S
    BMC Immunol; 2017 Jun; 18(1):31. PubMed ID: 28633645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes.
    Kono K; Rongcun Y; Charo J; Ichihara F; Celis E; Sette A; Appella E; Sekikawa T; Matsumoto Y; Kiessling R
    Int J Cancer; 1998 Oct; 78(2):202-8. PubMed ID: 9754653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
    Song S; Wang F; He X; He Y; Li D; Sun S
    Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
    Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
    Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A modified HLA-A*0201-restricted CTL epitope from human oncoprotein (hPEBP4) induces more efficient antitumor responses.
    Sun W; Shi J; Wu J; Zhang J; Chen H; Li Y; Liu S; Wu Y; Tian Z; Cao X; Li N
    Cell Mol Immunol; 2018 Aug; 15(8):768-781. PubMed ID: 29375131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
    Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
    Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
    Knutson KL; Schiffman K; Cheever MA; Disis ML
    Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.
    Disis ML; Smith JW; Murphy AE; Chen W; Cheever MA
    Cancer Res; 1994 Feb; 54(4):1071-6. PubMed ID: 7508819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors.
    Seavey MM; Pan ZK; Maciag PC; Wallecha A; Rivera S; Paterson Y; Shahabi V
    Clin Cancer Res; 2009 Feb; 15(3):924-32. PubMed ID: 19188163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.
    Knutson KL; Schiffman K; Disis ML
    J Clin Invest; 2001 Feb; 107(4):477-84. PubMed ID: 11181647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy.
    Scardino A; Gross DA; Alves P; Schultze JL; Graff-Dubois S; Faure O; Tourdot S; Chouaib S; Nadler LM; Lemonnier FA; Vonderheide RH; Cardoso AA; Kosmatopoulos K
    J Immunol; 2002 Jun; 168(11):5900-6. PubMed ID: 12023395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Her-2/ neu altered peptide ligand-induced CTL responses: implications for peptides with increased HLA affinity and T-cell-receptor interaction.
    Dionne SO; Myers CE; Smith MH; Lake DF
    Cancer Immunol Immunother; 2004 Apr; 53(4):307-14. PubMed ID: 14605764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues.
    Vertuani S; Sette A; Sidney J; Southwood S; Fikes J; Keogh E; Lindencrona JA; Ishioka G; Levitskaya J; Kiessling R
    J Immunol; 2004 Mar; 172(6):3501-8. PubMed ID: 15004150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors.
    Scardino A; Alves P; Gross DA; Tourdot S; Graff-Dubois S; Angevin E; Firat H; Chouaib S; Lemonnier F; Nadler LM; Cardoso AA; Kosmatopoulos K
    Eur J Immunol; 2001 Nov; 31(11):3261-70. PubMed ID: 11745343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction.
    Fisk B; Savary C; Hudson JM; O'Brian CA; Murray JL; Wharton JT; Ioannides CG
    J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):197-209. PubMed ID: 8680648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.
    Gritzapis AD; Voutsas IF; Baxevanis CN
    Cancer Immunol Immunother; 2012 Mar; 61(3):397-407. PubMed ID: 21928125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient.
    Knutson KL; Disis ML
    Hum Immunol; 2002 Jul; 63(7):547-57. PubMed ID: 12072190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
    Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
    Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.